Please login to the form below
Claire Derbyshire joins Cello Health Insight UK
She becomes a director at the healthcare market research agency
Cello Health Insight has appointed Claire Derbyshire as a director at its UK office, strengthening the agency's European client services team.
Derbyshire joins the healthcare market research firm from Infosys BPO, where she served as a global market intelligence and insight manager consulting for GlaxoSmithKline.
Previously, she served as head of decision support at Sanofi-Aventis, leading the company's Insight Program, having been promoted from market research manager.
Derbyshire also brings experience from Boehringer Ingelheim, where she held a business intelligence role, and from Bristol-Myers Squibb as a market research executive.
Paul O'Shaughnessy, global head of business development said: “We are very fortuitous to have Claire as part of our team, her wealth of experience and unique perspective will be very valuable to our clients and Cello Health Insight.”
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
fox&cat
Fox&cat is an award-winning healthcare communications agency which creates inspirational campaigns and programmes that exceed expectations. Priding itself on delivering...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
